Non-Invasive, Inhaler Solution for Postpartum Hemorrhage
Inhaled Oxytocin for Postpartum Haemorrhage
Tags: Monash University, Australia, Healthcare & Lifesciences
This novel oxytocin inhaler offers a non-invasive, heat-stable solution for preventing and treating postpartum hemorrhage (PPH), a major cause of maternal mortality. It activates uterine contractions via pulmonary delivery, reducing the need for refrigeration and skilled administration. Developed by Monash University, it has reached Phase 2 clinical trials, showing efficacy comparable to intramuscular injections. The technology is especially beneficial in low-resource settings, promising to save lives by making PPH treatment more accessible.
IP Type or Form Factor: Patent Granted; Process & Method; Material
TRL: 5 - prototype ready for testing in intended environment
Industry or Tech Area: Pharmaceutical Engineering; Medical Devices
